Recruiting studies: Sodium Glucose Co Transporter 2 Inhibitors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
Phase 4 · 2 location(s) · National Taiwan University Hospital · NCT06249945 SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
Phase 3 · 8 location(s) · The George Institute · NCT05345327 The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population
Phase 4 · 1 location(s) · Ahmed Yehia Ismail · NCT07700940 Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Dise
Phase 4 · 1 location(s) · Centenario Hospital Miguel Hidalgo · NCT07405216 Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease
Phase 4 · 2 location(s) · National Taiwan University Hospital · NCT06249932 Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
EARLY_Phase 1 · 1 location(s) · Ann & Robert H Lurie Children's Hospital of Chicago · NCT06430684

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.